Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9GZV9
UPID:
FGF23_HUMAN
Alternative names:
Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
Alternative UPACC:
Q9GZV9; Q4V758
Background:
Fibroblast growth factor 23 (FGF23), also known as Phosphatonin and Tumor-derived hypophosphatemia-inducing factor, plays a pivotal role in phosphate homeostasis. It inhibits renal tubular phosphate transport, up-regulates EGR1 expression, and acts on the parathyroid to decrease PTH secretion. FGF23 is a key regulator of vitamin-D metabolism and negatively regulates osteoblast differentiation.
Therapeutic significance:
FGF23 is implicated in Hypophosphatemic rickets, autosomal dominant, characterized by renal phosphate wasting, and Tumoral calcinosis, hyperphosphatemic, familial, 2, marked by hyperphosphatemia and calcium deposits. Understanding the role of FGF23 could open doors to potential therapeutic strategies for these conditions.